Keith Katkin
Chairman at ELEDON PHARMACEUTICALS, INC.
Net worth: 1 M $ as of 2024-04-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Dennis Podlesak | M | 66 |
Peninsula Pharmaceuticals, Inc.
 Peninsula Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Peninsula Pharmaceuticals, Inc. used to develop and commercialize antibiotics to treat life threatening infections. The company used to develop optimal anti-infective therapies that offer improved efficacy, dosing and safety characteristics over existing therapies. It was founded in 2001. The company was located in Alameda, CA.
Transposon Therapeutics, Inc.
 Transposon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Transposon Therapeutics, Inc. provides pharmaceutical products. The company is headquartered in Westport, CT. | 20 years |
| Christine Ocampo | F | 51 |
Urovant Sciences, Inc.
 Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 16 years |
| Bryan Smith | M | 45 |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 6 years |
| James Robinson | M | 54 | 5 years | |
| Pierre Legault | M | 63 |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 7 years |
| Sef P. Kurstjens | M | 60 |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 6 years |
| Michael Metzger | M | 53 | 9 years | |
| Shigeyuki Nishinaka | M | 59 |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 5 years |
| Myrtle Potter | F | 65 |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 6 years |
| Marvin White | M | 61 |
Indiana University
| 7 years |
| Gregg Lapointe | M | 65 | 7 years | |
| Steven Perrin | M | 59 | 4 years | |
| Keith Goldan | M | 52 | 2 years | |
| Zsolt Pál Harsányi | M | 80 | 20 years | |
| Eckard Weber | M | 73 |
Peninsula Pharmaceuticals, Inc.
Peninsula Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Peninsula Pharmaceuticals, Inc. used to develop and commercialize antibiotics to treat life threatening infections. The company used to develop optimal anti-infective therapies that offer improved efficacy, dosing and safety characteristics over existing therapies. It was founded in 2001. The company was located in Alameda, CA.
Transposon Therapeutics, Inc.
Transposon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Transposon Therapeutics, Inc. provides pharmaceutical products. The company is headquartered in Westport, CT. | - |
| Jennifer Jarrett | F | 53 | 6 years | |
| Donald DeGolyer | M | 63 | 1 years | |
| David-Alexandre Gros | M | 51 | 4 years | |
| Jennifer Fox | F | 51 | 6 years | |
| Alison Hannah | M | 63 | 3 years | |
| Neil Gallagher | M | 60 | 1 years | |
| Kathryn Zoon | M | 75 | 8 years | |
| June Lee | M | 58 | 4 years | |
| Brian Kotzin | M | 74 | 7 years | |
| Jan Hillson | M | 71 | 3 years | |
| Nori Ebersole | F | 60 |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 7 years |
| Paul Little | M | 60 | 3 years | |
| David Hovland | M | - | 6 years | |
| Catherine Madigan | M | 52 | - | |
| Kelly Parker | M | - | 9 years | |
| Richard Lindahl | M | 70 | 6 years | |
| Allan Kirk | M | - | 1 years | |
| Jane Wasman | F | 67 | 5 years | |
| Joseph Papa | M | 68 | - | |
| Luke Albrecht | M | 45 | 8 years | |
| Ronald Richard | M | 68 | 19 years | |
| Sharon P. Klahre | F | - | 2 years | |
| William Meury | M | 56 | 6 years | |
| Neal Fowler | M | 62 | 1 years | |
| John McBride | M | 72 | 7 years | |
| Peter Ordentlich | M | 55 | 19 years | |
| Kamil Ali-Jackson | F | 65 | 3 years | |
| Walter Ogier | M | 67 | 4 years | |
| Martin Huber | M | 64 | 3 years | |
| Sujata Dayal | F | 61 | 2 years | |
| Louis Sullivan | M | 90 | 19 years | |
| Stephanie Duatschek | F | - | - | |
| Michelle Pepin | F | - | 1 years | |
| Aubrey Watkins | M | - | - | |
| Anjali Ganguli | M | 48 | 9 years | |
| Sharon Solomon | F | - | 7 years | |
| Kevin McManus | M | - | 1 years | |
| Brent Ahrens | M | 61 |
Transposon Therapeutics, Inc.
Transposon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Transposon Therapeutics, Inc. provides pharmaceutical products. The company is headquartered in Westport, CT. | - |
| Cornelia Haag-Molkenteller | M | 66 |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 6 years |
| Heather N. Vinas | F | 44 |
Brain Injury Association of America, Inc.
| - |
| Hisanori Maei | M | - | 9 years | |
| Brent E. Masel | M | - |
Brain Injury Association of America, Inc.
| - |
| Laura Kennedy | F | - | 8 years | |
| Dean Schorno | M | 61 | 6 years | |
| Jack A. Bowling | M | - |
Brain Injury Association of America, Inc.
| - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Robert Kramer | M | 66 | 24 years | |
| Jon S. Kuwahara | M | 59 | 7 years | |
| Richard Shea | M | 72 | 6 years | |
| Fuad El Hibri | M | 66 | 24 years | |
| Rohan Palekar | M | 58 | 5 years | |
| Michael McFadden | M | 57 |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 9 years |
| Erez Chimovits | M | 60 |
Otic Pharma Ltd.
 Otic Pharma Ltd. Pharmaceuticals: MajorHealth Technology Otic Pharma Ltd. develops and manufactures pharmaceutical products for ear indications. Its products include FoamOtic Externa, FoamOtic Sinus, Foam-O-Vet, and FoamOtic Media. The company was founded by Gad Riesenfeld, Rodrigo A. Yelin and Eran Eilat in March 2008 and is headquartered in Irvine, CA. | 3 years |
| Gregory P. Hanson | M | 77 | 8 years | |
| Jodie Morrison | F | 48 | 5 years | |
| Gregory Flesher | M | 54 | 13 years | |
| Briggs Morrison | M | 65 | 9 years | |
| Catherine Turkel | M | 63 |
Otic Pharma Ltd.
Otic Pharma Ltd. Pharmaceuticals: MajorHealth Technology Otic Pharma Ltd. develops and manufactures pharmaceutical products for ear indications. Its products include FoamOtic Externa, FoamOtic Sinus, Foam-O-Vet, and FoamOtic Media. The company was founded by Gad Riesenfeld, Rodrigo A. Yelin and Eran Eilat in March 2008 and is headquartered in Irvine, CA. | 5 years |
| Michael Cruse | M | 52 | 14 years | |
| Atul Saran | M | 50 | 6 years | |
| Alexander Nolte | M | 52 | 6 years | |
| Eric Brandt | M | 62 | 2 years | |
| Donald G. Payan | M | 75 | 20 years | |
| Bruce E. Beerbower | M | - |
Indiana University
| 5 years |
| Terry Stapp | M | - |
Indiana University
| 8 years |
| Keith M. McGahan | M | - | 1 years | |
| Jerome Hauer | M | 72 | 8 years | |
| Scott Whitcup | M | 64 | 9 years | |
| Adam Havey | M | 53 | 20 years | |
| Henry Chen | M | 53 | 3 years | |
| George W. Sledge | M | 73 | 3 years | |
| Michael Meyers | M | 74 | 7 years | |
| Fabrice Egros | M | 62 | 9 years | |
| Cheryl Cohen | F | 58 | 5 years | |
| Steven Basta | M | 59 |
Carbylan Therapeutics, Inc.
 Carbylan Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Carbylan Therapeutics, Inc. engages in the development and market of medical devices and drug combination products to treat the pain associated with osteoarthritis. It offers Hydros Joint Therapy and Hydros-TA Joint Therapy, viscoelastic hyaluronan-based products designed to provide long term relief of the pain associated with osteoarthritis using a single intra-articular injection. The company was founded by Richard R. Orlandi, Albert Park, Glenn D. Prestwich and Richard K. Koehn in March 2004 and is headquartered in Palo Alto, CA. | 7 years |
| David M. Clapper | M | 72 |
Carbylan Therapeutics, Inc.
Carbylan Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Carbylan Therapeutics, Inc. engages in the development and market of medical devices and drug combination products to treat the pain associated with osteoarthritis. It offers Hydros Joint Therapy and Hydros-TA Joint Therapy, viscoelastic hyaluronan-based products designed to provide long term relief of the pain associated with osteoarthritis using a single intra-articular injection. The company was founded by Richard R. Orlandi, Albert Park, Glenn D. Prestwich and Richard K. Koehn in March 2004 and is headquartered in Palo Alto, CA. | 2 years |
| Hans Bishop | M | 59 | 3 years | |
| Bob Miller | M | - |
Indiana University
| 8 years |
| Katherine Strei | F | 62 | 7 years | |
| Don Bobbs | M | - |
Indiana University
| 9 years |
| Craig Wheeler | M | 63 | 10 years | |
| Stephen G. Austin | M | 71 | 9 years | |
| David Saul | M | - |
Carbylan Therapeutics, Inc.
Carbylan Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Carbylan Therapeutics, Inc. engages in the development and market of medical devices and drug combination products to treat the pain associated with osteoarthritis. It offers Hydros Joint Therapy and Hydros-TA Joint Therapy, viscoelastic hyaluronan-based products designed to provide long term relief of the pain associated with osteoarthritis using a single intra-articular injection. The company was founded by Richard R. Orlandi, Albert Park, Glenn D. Prestwich and Richard K. Koehn in March 2004 and is headquartered in Palo Alto, CA. | - |
| Mark Corrigan | M | 66 | 1 years | |
| Kim Kamdar | M | 56 | 11 years | |
| Anand Deshpande | M | 62 |
Indiana University
| 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 100 | 100.00% |
| Bermuda | 9 | 9.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Keith Katkin
- Personal Network
